LXRX - Lexicon Pharmaceuticals, Inc.
1.9900 -0.04 (-0.02%)
Pre-Market: 9:16AM EDT
Chart Events
Performance Outlook
- Short Term2W - 6W
- Mid Term6W - 9M
- Long Term9M+
| Previous Close | 1.9550 |
| Open | 1.9700 |
| Bid | 1.9800 x 1000 |
| Ask | 2.0200 x 1300 |
| Day's Range | 1.8700 - 2.0300 |
| 52 Week Range | 1.1300 - 6.7200 |
| Volume | 858,053 |
| Avg. Volume | 956,127 |
| Market Cap | 217.15M |
| Beta (5Y Monthly) | 1.11 |
| PE Ratio (TTM) | 2.63 |
| EPS (TTM) | 0.7730 |
| Earnings Date | Jul 29, 2020 - Aug 03, 2020 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 4.70 |
- GlobeNewswire
Lexicon Pharmaceuticals to Present at Upcoming Investor Conference
The audio webcast for this conference will be available in the “Events” section of the Lexicon website at www.lexpharma.com/. Through the precise targeting of these proteins, Lexicon is pioneering the discovery and development of innovative medicines to safely and effectively treat disease. In addition to its first commercial product, XERMELO, Lexicon has a pipeline of promising drug candidates in clinical and preclinical development in diabetes and metabolism, oncology and neuropathic pain.
- GlobeNewswire
Lexicon Pharmaceuticals Announces Preclinical Efficacy Data on Telotristat Ethyl’s Antiproliferative Effects Against Various Cancer Cell Lines
Lexicon Pharmaceuticals, Inc. (LXRX), announced today additional data on XERMELO’s® (telotristat ethyl) antiproliferative effects against cultured liposarcoma, colon cancer and cholangiocarcinoma cell lines that were published online in conjunction with the American Society of Clinical Oncology (ASCO) 2020 annual meeting (May 29 - June 2, 2020). XERMELO is approved for the treatment of carcinoid syndrome diarrhea in combination with somatostatin analog (SSA) therapy in adults inadequately controlled by SSA therapy, but is not currently approved for any other use.
- Thomson Reuters StreetEvents
Edited Transcript of LXRX earnings conference call or presentation 27-Apr-20 12:00pm GMT
Q1 2020 Lexicon Pharmaceuticals Inc Earnings Call
- Motley Fool
Why Lexicon Pharmaceuticals Stock Soared Today
The biotech company reported better-than-expected first-quarter results and now sees lower costs in 2020.
- Zacks
Lexicon Pharmaceuticals (LXRX) Reports Q1 Loss, Tops Revenue Estimates
Lexicon (LXRX) delivered earnings and revenue surprises of 4.55% and 11.47%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?
- Benzinga
Lexicon Pharmaceuticals: Q1 Earnings Insights
Shares of Lexicon Pharmaceuticals (NASDAQ:LXRX) were flat in pre-market trading after the company reported Q1 results.Quarterly Results Earnings per share decreased 200.00% over the past year to ($0.63), which beat the estimate of ($0.69).Revenue of $7,999,000 lower by 13.21% from the same period last year, which beat the estimate of $7,790,000.Guidance Lexicon Pharmaceuticals hasn't issued any earnings guidance for the time being.Revenue guidance hasn't been issued by the company for now.How To Listen To The Conference Call Date: Apr 27, 2020View more earnings on LXRXTime: 02:04 PM ETWebcast URL: http://www.lexpharma.com/investorsPrice Action Company's 52-week high was at $7.2752-week low: $1.12Price action over last quarter: Up 1.97%Company Profile Lexicon Pharmaceuticals Inc is a biopharmaceutical company developing medicines that transform patients' lives. The company commercializes and develops drugs and drug candidates. Its drugs candidates include XERMELO (telotristat ethyl), an orally-delivered small molecule drug, in the United States for the treatment of carcinoid syndrome diarrhea in combination with somatostatin analog, or SSA, therapy in adults inadequately controlled by SSA therapy; Zynquista (sotagliflozin), an orally-delivered small molecule drug candidate, as a treatment for type 1 diabetes; sotagliflozin as a treatment for type 2 diabetes, heart failure and chronic kidney disease; and LX9211, an orally-delivered small molecule drug candidate, as a treatment for neuropathic pain.See more from Benzinga * 6 Real Estate Stocks Moving In Monday's Pre-Market Session * Affiliated Managers Group: Q1 Earnings Insights * 6 Financial Services Stocks Moving In Monday's Pre-Market Session(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
- GlobeNewswire
LEXICON PHARMACEUTICALS REPORTS FIRST QUARTER 2020 FINANCIAL RESULTS AND PROVIDES A BUSINESS UPDATE
THE WOODLANDS, Texas, April 27, 2020 -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), today reported financial results and provided a business update for the three months ended.
- GlobeNewswire
Lexicon Pharmaceuticals to Host First Quarter 2020 Financial Results Conference Call and Webcast On April 27, 2020
Lexicon Pharmaceuticals, Inc. (LXRX) will release its first quarter 2020 financial results on Monday, April 27, 2020 before market opens. Management will conduct a conference call and live webcast at 8:00 a.m. ET (7:00 a.m. CT) that day to discuss the financial results and to provide a business update.
- Simply Wall St.
The Lexicon Pharmaceuticals (NASDAQ:LXRX) Share Price Is Down 88% So Some Shareholders Are Rather Upset
As an investor, mistakes are inevitable. But really big losses can really drag down an overall portfolio. So consider...
- GlobeNewswire
LEXICON PHARMACEUTICALS TO HOST VIRTUAL ANNUAL MEETING OF STOCKHOLDERS ON APRIL 23, 2020
Lexicon Pharmaceuticals, Inc. (LXRX) will host its 2020 annual meeting of stockholders in a virtual format only due to the public health impact of the coronavirus pandemic and to prioritize the health and well-being of meeting participants. The virtual 2020 annual meeting of stockholders will be held at 8:00 a.m. CT on April 23, 2020. Stockholders at the close of business on the record date, February 24, 2020, are entitled to attend the annual meeting.
- Thomson Reuters StreetEvents
Edited Transcript of LXRX earnings conference call or presentation 12-Mar-20 12:00pm GMT
Q4 2019 Lexicon Pharmaceuticals Inc Earnings Call
- Benzinga
The Daily Biotech Pulse: Mylan Ramps Up Manufacturing Of Potential COVID-19 Drug, Lexicon Stops Study Early, Masimo To Buy German Ventilation Company
Here's a roundup of top developments in the biotech space over the last 24 hours:Scaling The Peaks (Biotech stocks that hit 52-week highs March 19.) * Biomerica, Inc. (NASDAQ: BMRA) * Centogene NV (NASDAQ: CNTG) * Gilead Sciences, Inc. (NASDAQ: GILD) * Imara Inc (NASDAQ: IMRA) * Regeneron Pharmaceuticals Inc (NASDAQ: REGN)Down In The Dumps (Biotech stocks that hit 52-week lows March 19.) * Acasti Pharma Inc (NASDAQ: ACST) * Accelerate Diagnostics Inc (NASDAQ: AXDX) * Acer Therapeutics Inc (NASDAQ: ACER) * Aclaris Therapeutics Inc (NASDAQ: ACRS) * Aerpio Pharmaceuticals Inc (NASDAQ: ARPO) * Aikido Pharma Inc (NASDAQ: AIKI) * Alpine Immune Sciences Inc (NASDAQ: ALPN) * Amphastar Pharmaceuticals Inc (NASDAQ: AMPH) * Anika Therapeutics Inc (NASDAQ: ANIK) * Anixa Biosciences Inc (NASDAQ: ANIX) * AnPac Bio-Medical Science Co Ltd - ADR (NASDAQ: ANPC) * Antares Pharma Inc (NASDAQ: ATRS) * Apyx Medical Corp (NASDAQ: APYX) * Arca Biopharma Inc (NASDAQ: ABIO) * Aridis Pharmaceuticals Inc (NASDAQ: ARDS) * aTyr Pharma Inc (NASDAQ: LIFE) * AVEO Pharmaceuticals, Inc. (NASDAQ: AVEO) * Axonics Modulation Technologies Inc (NASDAQ: AXNX) * Bellerophon Therapeutics Inc (NASDAQ: BLPH) * BioCardia Inc (NASDAQ: BCDA) * Brickell Biotech Inc (NASDAQ: BBI) * Cabaletta Bio Inc (NASDAQ: CABA) * Caladrius Biosciences Inc (NASDAQ: CLBS) * Cara Therapeutics Inc (NASDAQ: CARA) * Cancer Genetics Inc (NASDAQ: CGIX) * Catalyst Biosciences Inc (NASDAQ: CBIO) * Celldex Therapeutics, Inc. (NASDAQ: CLDX) * Chiasma Inc (NASDAQ: CHMA) * Chimerix Inc (NASDAQ: CMRX) * DarioHealth Corp (NASDAQ: DRIO) * DelMar Pharmaceuticals Inc (NASDAQ: DMPI) * Exicure Inc (NASDAQ: XCUR) * Eyenovia Inc (NASDAQ: EYEN) * Eyepoint Pharmaceuticals Inc (NASDAQ: EYPT) * FibroGen Inc (NASDAQ: FGEN) * Galmed Pharmaceuticals Ltd (NASDAQ: GLMD) * GlaxoSmithKline plc (NYSE: GSK) * Happiness Biotech Group Ltd (NASDAQ: HAPP) * Hoth Therapeutics Inc (NASDAQ: HOTH) * HTG Molecular Diagnostics Inc (NASDAQ: HTGM) * Kura Oncology Inc (NASDAQ: KURA) * MEI Pharma Inc (NASDAQ: MEIP) * Merrimack Pharmaceuticals Inc (NASDAQ: MACK) * Merus NV (NASDAQ: MRUS) * Mesoblast limited (NASDAQ: MESO) * Miragen Therapeutics Inc (NASDAQ: MGEN) * Morphosys Ag (NASDAQ: MOR) * Nabriva Therapeutics PLC - ADR (NASDAQ: NBRV) * Natus Medical Inc (NASDAQ: NTUS) * Neovasc Inc (NASDAQ: NVCN) * Novus Therapeutics Inc (NASDAQ: NVUS) * Opiant Pharmaceuticals Inc (NASDAQ: OPNT) * OptiNose Inc (NASDAQ: OPTN) * PLx Pharma Inc (NASDAQ: PLXP) * PRA Health Sciences Inc (NASDAQ: PRAH) * Precipio Inc (NASDAQ: PRPO) * Psychemedics Corp. (NASDAQ: PMD) * Quest Diagnostics Inc (NYSE: DGX) * Replimune Group Inc (NASDAQ: REPL) * resTORbio, Inc. (NASDAQ: TORC) * Rexahn Pharmaceuticals, Inc. (NASDAQ: REXN) * Rigel Pharmaceuticals, Inc. (NASDAQ: RIGL) * Salarius Pharmaceuticals Inc (NASDAQ: SLRX) * Silk Road Medical Inc (NASDAQ: SILK) * Spectrum Pharmaceuticals, Inc. (NASDAQ: SPPI) * STRATA Skin Sciences Inc (NASDAQ: SSKN) * Sutro Biopharma Inc (NASDAQ: STRO) * TELA Bio Inc (NASDAQ: TELA) * Titan Medical Inc. (NASDAQ: TMDI) * Trinity Biotech plc (NASDAQ: TRIB) * TrovaGene Inc (NASDAQ: TROV) * Vericel Corp (NASDAQ: VCEL) * Xenetic Biosciences Inc (NASDAQ: XBIO) * Xeris Pharmaceuticals Inc (NASDAQ: XERS) * Y-mAbs Therapeutics, Inc (NASDAQ: YMAB) * Zafgen Inc (NASDAQ: ZFGN)See also: 8 Biotechs With Coronavirus Vaccines In Development Stocks In Focus Mylan Ramps Up Production Of Malaria Medication To Potentially Treat COVID-19 Generic drugmaker Mylan NV (NASDAQ: MYL) said it has restarted production of hydrochloroquine sulfate tablets at a West Virginia manufacturing facility to meet the potential for increased demand due to its potential effectiveness in treating COVID-19.These tablets are approved by the FDA to treat malaria, lupus erythematosus and rheumatoid arthritis.The product, though not currently approved for use in treating COVID-19, is listed by the WHO as a drug under investigation for efficacy against the coronavirus.Mylan said it can begin supplying the product by mid-April, and with the active pharmaceutical ingredient it currently has, it can ramp up manufacturing to provide 50 million tablets to potentially treat more than 1.5 million patients.The stock was trading 16.14% higher to $17.27 in Friday's premarket session.Benzinga is covering every angle of how the coronavirus affects the financial world. For daily updates, sign up for our coronavirus special edition newsletter.Lexicon Closes Out 2 Long-Term Zynquista Studies Due To Resource Crunch, COVID-19 Lexicon Pharmaceuticals, Inc. (NASDAQ: LXRX) said it will close out early two long-term outcome studies of Type 1 diabetes drug Zynquista, dubbed SCORED and SOLOIST, citing the unlikelihood of the materialization of a near-term partnership that was expected to fund the studies and the uncertainties related to the effects of the COVID-19 pandemic on trial results.These two studies were meant to assess the benefits of the drug and support labeling for heart failure and chronic kidney disease.View more earnings on IBBLexicon said it hopes it has has sufficient exposure data and cardiovascular events to satisfy all requirements for Type 2 diabetes. This shift, according to the company, will help conserve financial resources and prioritize its portfolio to advance pipeline drugs such as telotristat ethyl in biliary tract cancer and LX9211 in neuropathic pain.Masimo Exercises Option To Buy Ventilation Company TNI Medical Masimo Corporation (NASDAQ: MASI) said it has entered into a definitive agreement to acquire German ventilation company TNI medical AG. In August 2019, Masimo disclosed an investment in TNI that included an exclusive option to buy the company."Due to COVID-19, there has been increasing demand for TNI's softFlow technology," Masimo CEO Joe Kiani said in a statement. "We believe this technology will provide clinicians with important additional tools to address the growing number of people affected by pulmonary diseases and respiratory-related illnesses, including those suffering from COVID-19."Earnings Moleculin Biotech Inc (NASDAQ: MBRX) reported a narrower loss of 32 cents per share in the fourth quarter of 2019. The company said its cash reserves at the end of 2019 and additional funding received subsequent to the end of the year will suffice to meet it operating expenses through the third quarter of 2020.In premarket trading Friday, Moleculin shares were gaining 13.85% to 74 cents.Vaxart Inc's (NASDAQ: VXRT) fourth-quarter loss narrowed from 69 cents in 2018 to 13 cents in 2019, in line with the consensus estimate. Revenues rose from $1.77 million to $3.92 million.The stock was trading 15.1% higher at $2.21 in Friday's premarket session.Related Link:The Week Ahead In Biotech: COVID-19 Updates, Tapering Earnings Flow, Eton's Seizure Drug Review See more from Benzinga * 12 Key Medical Meetings Canceled Or Postponed In The Face Of A Pandemic * The Daily Biotech Pulse: Pfizer's Eczema Drug Aces Latestage Study, Orphan Drug Designation For Dicerna, Dyadic's COVID-19 Connection * The Daily Biotech Pulse: AbbVie, Allergan Agree On Divestments, Obalon Stops Obesity Balloon Sale, COVID-19 Updates(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
- GlobeNewswire
LEXICON PHARMACEUTICALS PROVIDES AN UPDATE ON THE SOTAGLIFLOZIN TYPE 2 DIABETES PROGRAM
Lexicon Pharmaceuticals, Inc. (LXRX), today provided an update on its ZynquistaTM (sotagliflozin) program in type 2 diabetes, heart failure and chronic kidney disease. The company will close out early the two long-term outcomes studies of sotagliflozin, SCORED and SOLOIST, designed to demonstrate benefits in and support labeling for heart failure and chronic kidney disease. The decision to close out the studies early is based principally on the company’s assessment that a near-term partnership sufficient to fund the studies to completion is now unlikely, together with uncertainties relating to the effects of the COVID-19 pandemic on the trials.
- GlobeNewswire
LEXICON PHARMACEUTICALS ANNOUNCES ADDITIONAL DATA ON TELOTRISTAT ETHYL’S ANTIPROLIFERATIVE EFFECTS IN PATIENTS WITH CARCINOID SYNDROME
Lexicon Pharmaceuticals, Inc. (LXRX), announced today additional data on XERMELO’s® (telotristat ethyl) antiproliferative effects in patients with carcinoid syndrome that were presented at the European Neuroendocrine Tumor Society (ENETS) meeting (March 11-13). XERMELO is approved for the treatment of carcinoid syndrome diarrhea in combination with somatostatin analog (SSA) therapy in adults inadequately controlled by SSA therapy, but is not currently approved for any other use. Data from a retrospective, pre- and post-design chart review of 200 metastatic neuroendocrine tumor patients who were on standard background therapies and received telotristat ethyl for an average of 12 months in US clinical practice demonstrated that most patients had no tumor progression at 6, 12 and 18 months following initiation of telotristat ethyl, with a median time to tumor progression (TTP) of 39.8 months.
- Benzinga
Lexicon Pharmaceuticals: Q4 Earnings Insights
Lexicon Pharmaceuticals (NASDAQ:LXRX) reported Q4 results.Quarterly Results • Earnings per share came in at a loss of $0.48, which beat the estimate calling for a loss of $0.77.• Revenue of $8,727,000 lower by 48.88% from the same period last year, which missed the estimate of $10,260,000.How To Listen To The Conference Call • Date: Mar 12, 2020View more earnings on LXRX• Webcast URL: http://www.lexpharma.com/investorsTechnicals • 52-week high was at $8.39• 52-week low: $1.12• Price action over last quarter: Up 42.90%Company Description Lexicon Pharmaceuticals is a biopharmaceutical company that uses mouse genetics to discover the function of genes and find promising drug targets. Lexicon then designs and develops drugs for these targets, which cover a broad spectrum of therapeutic areas. Following a restructuring in January 2014, Lexicon focused efforts on two drugs: sotagliflozin in diabetes, which is partnered with Sanofi, and Xermelo (telotristat etiprate) in carcinoid syndrome, which is partnered with Ipsen outside the U.S. Early-stage programs include SGLT1 inhibitor LX2761 and neuropathic pain drug LX9211.See more from Benzinga * 15 Biotechnology Stocks Moving In Thursday's After-Market Session * 20 Healthcare Stocks Moving In Thursday's After-Market Session * 146 Biotechnology Stocks Moving In Thursday's Session(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
- Zacks
Lexicon Pharmaceuticals (LXRX) Reports Q4 Loss, Misses Revenue Estimates
Lexicon (LXRX) delivered earnings and revenue surprises of 36.84% and -17.62%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?
- GlobeNewswire
LEXICON PHARMACEUTICALS REPORTS FOURTH QUARTER AND FULL-YEAR 2019 FINANCIAL RESULTS AND PROVIDES A BUSINESS UPDATE
XERMELO® (telotristat ethyl) 2019 U.S. Net Sales Reached $31.0 Million THE WOODLANDS, Texas, March 12, 2020 -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), today reported.
- GlobeNewswire
Lexicon Pharmaceuticals to Host Fourth Quarter and Full-Year 2019 Financial Results Conference Call and Webcast on March 12, 2020
THE WOODLANDS, Texas, March 05, 2020 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (LXRX), will release its fourth quarter and full-year 2019 financial results on Thursday, March 12, 2020 before market opens. Management will conduct a conference call and live webcast at 8:00 a.m. EST (7:00 a.m. CST) that day to discuss the financial results and to provide a business update.
- Zacks
Analysts Estimate Lexicon Pharmaceuticals (LXRX) to Report a Decline in Earnings: What to Look Out for
Lexicon (LXRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- GlobeNewswire
Lexicon Pharmaceuticals Announces Real-World Data on Telotristat Ethyl’s Antiproliferative Effects in Patients With Carcinoid Syndrome
Lexicon Pharmaceuticals, Inc. (LXRX), announced today real-world data on XERMELO’s® (telotristat ethyl) antiproliferative effects in patients with carcinoid syndrome that were presented at the American Society for Clinical Oncology (ASCO) 2020 Symposium (January 23-25, San Francisco, CA). XERMELO is approved for the treatment of carcinoid syndrome diarrhea in combination with somatostatin analog (SSA) therapy in adults inadequately controlled by SSA therapy, but is not currently approved for any other use. Data from a retrospective, pre- and post-design chart review of 200 metastatic neuroendocrine tumor patients who were on standard background therapies and received telotristat ethyl for an average of 12 months in US clinical practice demonstrated significant mean tumor size reduction of 0.59 cm after initiation of telotristat ethyl (p = 0.006).
- GlobeNewswire
Lexicon Pharmaceuticals Announces Poster Presentation at the ASCO 2020 Gastrointestinal Cancers Symposium
THE WOODLANDS, Texas, Jan. 20, 2020 -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), announced today that data from a poster highlighting XERMELO® (telotristat ethyl) will be.
- Simply Wall St.
Is Lexicon Pharmaceuticals (NASDAQ:LXRX) Using Too Much Debt?
Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...
- GlobeNewswire
Lexicon Pharmaceuticals Announces Topline Phase 3 Data for Sotagliflozin in Type 2 Diabetes
Lexicon Pharmaceuticals, Inc. (LXRX), today announced topline data from the Phase 3 SOTA-EMPA study for sotagliflozin (Zynquista™) in type 2 diabetes. Sotagliflozin 400 mg achieved the primary endpoint of superiority on A1C reduction versus placebo at Week 26 in patients with type 2 diabetes who have inadequate glycemic control on a dipeptidyl peptidase 4 inhibitor (DPP4i) with or without metformin.
- Insider Monkey
Were Hedge Funds Right About Betting On Lexicon Pharmaceuticals, Inc. (LXRX)?
We are still in an overall bull market and many stocks that smart money investors were piling into surged through the end of November. Among them, Facebook and Microsoft ranked among the top 3 picks and these stocks gained 54% and 51% respectively. Hedge funds' top 3 stock picks returned 41.7% this year and beat […]
